AB SCIENCE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.9 EUR | -2.06% |
|
-4.52% | -46.55% |
| Apr. 04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
| Apr. 03 | AB Science: reconsideration possible for masitinib in ALS | CF |
| Sales 2023 * | 930K 998K | Sales 2024 * | 990K 1.06M | Capitalization | 99.07M 106M |
|---|---|---|---|---|---|
| Net income 2023 * | -19M -20.38M | Net income 2024 * | -18M -19.31M | EV / Sales 2023 * | 107 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 100 x |
| P/E ratio 2023 * |
-5.11
x | P/E ratio 2024 * |
-5.39
x | Employees | 89 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on AB Science
More press releases
More news
| 1 day | -2.06% | ||
| 1 week | -4.52% | ||
| Current month | -24.90% | ||
| 1 month | -26.92% | ||
| 3 months | -49.67% | ||
| 6 months | -15.74% | ||
| Current year | -46.55% |
1 week
1.89
2.03
1 month
1.892.68
Current year
1.554.47
1 year
1.556.54
3 years
1.5516.68
5 years
1.5521.75
10 years
1.5521.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Laurent Guy
DFI | Director of Finance/CFO | - | 01-12-31 |
| Chief Tech/Sci/R&D Officer | - | 18-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alain Moussy
CEO | Chief Executive Officer | - | 01-07-10 |
Patrick Moussy
BRD | Director/Board Member | - | 01-07-10 |
| Director/Board Member | 62 | 21-06-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1.9 | -2.06% | 53 470 |
| 24-04-24 | 1.94 | -2.02% | 68,439 |
| 24-04-23 | 1.98 | -0.90% | 57,815 |
| 24-04-22 | 1.998 | +1.52% | 75,972 |
| 24-04-19 | 1.968 | -1.11% | 50,150 |
Real-time Euronext Paris, April 25, 2024 at 06:03 am EDT
More quotes
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q4 2023 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.94
EUR
Average target price
6.895
EUR
Spread / Average Target
+255.41%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -46.55% | 106M | |
| +4.30% | 70.78B | |
| +10.72% | 9.15B | |
| -15.34% | 4.84B | |
| +34.54% | 4.22B | |
| +5.09% | 3.92B | |
| +23.39% | 2.55B | |
| -28.33% | 2.24B | |
| -24.15% | 2.26B | |
| +6.23% | 1.92B |
- Stock Market
- Equities
- AB Stock
